193 related articles for article (PubMed ID: 15755631)
1. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer.
Adams M; Navabi H; Croston D; Coleman S; Tabi Z; Clayton A; Jasani B; Mason MD
Vaccine; 2005 Mar; 23(17-18):2374-8. PubMed ID: 15755631
[TBL] [Abstract][Full Text] [Related]
2. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial.
Navabi H; Croston D; Hobot J; Clayton A; Zitvogel L; Jasani B; Bailey-Wood R; Wilson K; Tabi Z; Mason MD; Adams M
Blood Cells Mol Dis; 2005; 35(2):149-52. PubMed ID: 16061407
[TBL] [Abstract][Full Text] [Related]
3. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
Baxevanis CN; Perez SA; Papamichail M
Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409
[TBL] [Abstract][Full Text] [Related]
5. Current approaches in ovarian cancer vaccines.
Reinartz S; Wagner U
Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
Tormo D; Ferrer A; Bosch P; Gaffal E; Basner-Tschakarjan E; Wenzel J; Tüting T
Cancer Res; 2006 May; 66(10):5427-35. PubMed ID: 16707471
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.
Kandimalla ER; Bhagat L; Li Y; Yu D; Wang D; Cong YP; Song SS; Tang JX; Sullivan T; Agrawal S
Proc Natl Acad Sci U S A; 2005 May; 102(19):6925-30. PubMed ID: 15860583
[TBL] [Abstract][Full Text] [Related]
8. Combining innate immunity with radiation therapy for cancer treatment.
Koski GK; Czerniecki BJ
Clin Cancer Res; 2005 Jan; 11(1):7-11. PubMed ID: 15671522
[No Abstract] [Full Text] [Related]
9. Immunologic approaches to ovarian cancer treatment.
Sabbatini P; Odunsi K
J Clin Oncol; 2007 Jul; 25(20):2884-93. PubMed ID: 17617519
[TBL] [Abstract][Full Text] [Related]
10. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
Conroy H; Marshall NA; Mills KH
Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
[TBL] [Abstract][Full Text] [Related]
11. Expression and function of Toll-like receptors in chicken heterophils.
Kogut MH; Iqbal M; He H; Philbin V; Kaiser P; Smith A
Dev Comp Immunol; 2005; 29(9):791-807. PubMed ID: 15936435
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of epithelial ovarian cancer].
Langmár Z; Csömör S
Orv Hetil; 2006 Aug; 147(34):1627-32. PubMed ID: 17017677
[TBL] [Abstract][Full Text] [Related]
13. Harnessing the immune system for ovarian cancer therapy.
Odunsi K; Sabbatini P
Am J Reprod Immunol; 2008 Jan; 59(1):62-74. PubMed ID: 18154597
[TBL] [Abstract][Full Text] [Related]
14. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
[TBL] [Abstract][Full Text] [Related]
15. The immunogenicity of dendritic cell-derived exosomes.
Quah BJ; O'Neill HC
Blood Cells Mol Dis; 2005; 35(2):94-110. PubMed ID: 15975838
[TBL] [Abstract][Full Text] [Related]
16. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
17. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
[TBL] [Abstract][Full Text] [Related]
18. Combined chemoimmunotherapy of solid tumours: improving vaccines?
Nowak AK; Lake RA; Robinson BW
Adv Drug Deliv Rev; 2006 Oct; 58(8):975-90. PubMed ID: 17005292
[TBL] [Abstract][Full Text] [Related]
19. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9.
Aurisicchio L; Peruzzi D; Conforti A; Dharmapuri S; Biondo A; Giampaoli S; Fridman A; Bagchi A; Winkelmann CT; Gibson R; Kandimalla ER; Agrawal S; Ciliberto G; La Monica N
Clin Cancer Res; 2009 Mar; 15(5):1575-84. PubMed ID: 19240169
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell immunotherapy for the treatment of neoplastic disease.
Decker WK; Xing D; Shpall EJ
Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
